WILMINGTON, DE — Incyte (Nasdaq: INCY) announced it will release its fourth-quarter and full-year 2025 financial results before the market opens on Tuesday, February 10, followed by a conference call and webcast for investors later that morning.
The biopharmaceutical company said its earnings press release will be issued at 7:00 a.m. Eastern time, with the conference call and live webcast scheduled for 8:00 a.m. Eastern time the same day.
Participants in the United States can access the call by dialing 877-407-3042, while international callers can dial 201-389-0864. The conference ID number is 13758313.
For those unable to participate live, a replay of the call will be available for 30 days. The U.S. replay number is 877-660-6853, and the international replay number is 201-612-7415. Callers will need to reference conference ID number 13758313 to access the replay.
A live webcast of the call, accompanied by presentation slides, will be available at https://Investor.Incyte.com and will remain accessible for replay for 90 days.
Headquartered in Wilmington, Delaware, Incyte is a global biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The company has established a portfolio of first-in-class medicines and maintains a development pipeline centered on Oncology and Inflammation and Autoimmunity, with operations spanning North America, Europe, and Asia.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.